Lithium extractant compounds having the following structure:

##STR00001##

wherein: R.sup.a and R.sup.b are independently selected from the group consisting of hydrocarbon groups (R), —OR, —NRR′, —SR, —SO.sub.2R, —SO.sub.2NR.sub.2, —C(O)R, —C(O)OR, —C(O)NRR′, —C(S)OR, —C(O)SR, and —C(S)NRR′; R′ is selected from R′ groups, wherein R′ is selected from H and R groups; X is O or OH; Y is C or N, wherein, when Y is N, then R.sup.a is R. Also described are hydrophobic water-insoluble solutions containing at least one extractant compound of Formula (1). Also described is a method for extracting lithium from an aqueous solution by contacting the aqueous solution with the hydrophobic solution, and optional stripping of lithium from the hydrophobic solution by contacting the hydrophobic solution with an aqueous stripping solution.

This invention provides a compound having the structure ##STR00001##
wherein α, β, X, Y, and R.sub.1-R.sub.11 are defined herein. This invention also provides a pharmaceutical composition comprising the above compounds, a method of inhibiting the activity and/or levels of a matrix metalloproteinase (MMP), a method of inhibiting the production of a cytokine in a population of cells, a method of inhibiting the production of a growth factor in a population of cells, and a method of inhibiting NFκ-B activation in a population of cells.

This invention provides a compound having the structure ##STR00001##
wherein α, β, X, Y, and R.sub.1-R.sub.11 are defined herein. This invention also provides a pharmaceutical composition comprising the above compounds, a method of inhibiting the activity and/or levels of a matrix metalloproteinase (MMP), a method of inhibiting the production of a cytokine in a population of cells, a method of inhibiting the production of a growth factor in a population of cells, and a method of inhibiting NFκ-B activation in a population of cells.

The invention relates to dioxomolybdenum (VI) complex compounds of the formula MoO.sub.2(L).sub.x(Y).sub.2-x, where the ligand L has the formula (I). Such complex compounds are suitable in particular as catalysts for one- and two-component polyurethane compositions. The invention also relates to two-component polyurethane compositions including at least one polyisocyanate as the first component, at least one polyol as the second component, and at least one such dioxomolybdenum (VI) complex compound as the catalyst. The invention further relates to one-component polyurethane compositions comprising at least one polyurethane prepolymer with isocyanate groups, which are made from at least one polyisocyanate with at least one polyol, and comprising such a dioxomolybdenum (VI) complex compound as the catalyst. The invention additionally relates to different uses of said polyurethane compositions. ##STR00001##

The invention relates to dioxomolybdenum (VI) complex compounds of the formula MoO.sub.2(L).sub.x(Y).sub.2-x, where the ligand L has the formula (I). Such complex compounds are suitable in particular as catalysts for one- and two-component polyurethane compositions. The invention also relates to two-component polyurethane compositions including at least one polyisocyanate as the first component, at least one polyol as the second component, and at least one such dioxomolybdenum (VI) complex compound as the catalyst. The invention further relates to one-component polyurethane compositions comprising at least one polyurethane prepolymer with isocyanate groups, which are made from at least one polyisocyanate with at least one polyol, and comprising such a dioxomolybdenum (VI) complex compound as the catalyst. The invention additionally relates to different uses of said polyurethane compositions. ##STR00001##

The invention relates to plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or disorder associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to prevent or reduce thrombosis and fibrosis, to promote thrombolysis, and to modulate lipid metabolism and treat diseases or disorders associated with elevated PAI-1, cholesterol, or lipid levels.

Non-lactone carbocyclic and heterocyclic antagonists and agonists of bacterial quorum sensing. Pharmaceutical composition containing antagonists. Methods employing antagonists and agonists for modulation of quorum sensing. Compounds are exemplified by those of formula:
A-[Z].sub.n-L1-[Y].sub.q-W-[V].sub.m-L2-HG,
where A is an acyclic aliphatic group, and HG is an optionally substituted phenyl group. Compounds include those where m and n are both 0, W is —NH—, Y is present and is —CO—CH.sub.2—CO—, and L1 and L2 independently are —[CH.sub.2].sub.p1— and —[CH.sub.2].sub.p2—, where p1 and p2, independently, are 0 or integers ranging from 1-10.

Non-lactone carbocyclic and heterocyclic antagonists and agonists of bacterial quorum sensing. Pharmaceutical composition containing antagonists. Methods employing antagonists and agonists for modulation of quorum sensing. Compounds are exemplified by those of formula:
A-[Z].sub.n-L1-[Y].sub.q-W-[V].sub.m-L2-HG,
where A is an acyclic aliphatic group, and HG is an optionally substituted phenyl group. Compounds include those where m and n are both 0, W is —NH—, Y is present and is —CO—CH.sub.2—CO—, and L1 and L2 independently are —[CH.sub.2].sub.p1— and —[CH.sub.2].sub.p2—, where p1 and p2, independently, are 0 or integers ranging from 1-10.

Compounds useful for treating or preventing diabetes and related conditions, and for preventing, inhibiting or reversing amylin-amyloid fibril formation, preventing islets of Langerhans (Beta)-cell death, preventing or reversing the transition from soluble human amylin to insoluble human amylin, preventing and inhibiting or reversing cytotoxic amylin fibril formation. The invention relates to compounds of Formula I and compounds of Formula II:

##STR00001##

This invention provides a compound having the structure

##STR00001##

wherein α, β, X, Y, and R.sub.1-R.sub.11 are defined herein. This invention also provides a pharmaceutical composition comprising the above compounds, a method of inhibiting the activity and/or levels of a matrix metalloproteinase (MMP), a method of inhibiting the production of a cytokine in a population of cells, a method of inhibiting the production of a growth factor in a population of cells, and a method of inhibiting NF.sub.K-B activation in a population of cells.